Lund, Sweden — 28 June 2018 — Camurus AB (Nasdaq STO, CAMX) has today updated its investor relations website to include a set of risk factors relevant to investors in the Company.
Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit www.camurus.com.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
Rein Piir, Investor Relations
Tel. +46 (0)70 853 72 92
The information was submitted for publication at 05.32 pm CET on 28 June 2018.